The Role of Hyperuricemia in the Development of Atrial Fibrillation

Abstract

Atrial fibrillation (AF) is one of the most common cardiac arrhythmias. We have discussed the role of hyperuricemia as a predisposing factor for the onset of AF. Numerous clinical and experimental investigators demonstrated the correlation between serum uric acid (SUA) level and arrhythmia development and its complications. The development and progression of AF are connected to a complex of changes in atrial cardiac muscle tissue. The electrical, structural, contractile remodeling, neurohumoral systems, inflammation, fibrosis, oxidative stress, endothelial dysfunction, activation of NLRP3 inflammasome induced by crystals of monosodium urate (MSU), heat shock proteins (HSP), cytokines – all have a role in the development of this process. Furthermore, the role of xanthine oxidase (XO) is considered in the pathogenesis of AF through activation of systemic inflammation and oxidative stress, preparing that substrate for AF. The overwhelming data suggest a direct pathophysiological role of the increased SUA and XO activity as risk factors for AF. This article offers a comprehensive review of investigations that shows the interrelation between hyperuricemia and the risk of AF.

Keywords

atrial fibrillation / uric acid / hyperuricemia / myocardial remodeling / oxidative stress / xanthine oxidase / uric acid transporters / heat shock proteins (HSP) / NLRP3 inflammasome / cytokines

References

[1] Taufiq F, Li P, Miake J, Hisatome I. Hyperuricemia as a risk factor for atrial fibrillation due to soluble and crystalized uric acid. Circ Rep. 2019;1(11):469–473. DOI: 10.1253/circrep.CR-19-0088

[2] Taufiq F., Li P., Miake J., Hisatome I. Hyperuricemia as a risk factor for atrial fibrillation due to soluble and crystalized uric acid // Circ. Rep. 2019. Vol. 1, No. 11. P. 469–473. DOI: 10.1253/circrep.CR-19-00882.

[3] Krijthe BP, Kunst A, Benjamin EJ, et al. Projections on the number of individuals with atrial fibrillation in the European Union, from 2000 to 2060. Eur Heart J. 2013;34(35):2746–2751. DOI: 10.1093/eurheartj/eht28027462751

[4] Krijthe B.P., Kunst A., Benjamin E.J., et al. Projections on the number of individuals with atrial fibrillation in the European Union, from 2000 to 2060 // Eur. Heart J. 2013. Vol. 34, No. 35. P. 2746–2751. DOI: 10.1093/eurheartj/eht2803.

[5] Zozulya IS, Gandzha TI, Suprun AO, Olefirenko AS. Provision of emergency medical care for atrial fibrillation. Medicina neotlozhnykh sostoyanij. 2016;3–4:60–61. (In Russ.).

[6] Зозуля И.С., Ганджа Т.И., Супрун А.О., Олефиренко А.С. Оказание неотложной медицинской помощи при фибрилляции предсердий // Медицина неотложных состояний. 2016. Т. 3–4. С. 60–61.

[7] Podzolkov VI, Tarzimanova AI, Gataulin RG, et al. The role of obesity in the development of atrial fibrillation: current problem status. Cardiovascular Therapy and Prevention. 2019;18(4):109–114. (In Russ.). DOI: 10.15829/1728-8800-2019-4-109-114

[8] Подзолков В.И., Тарзиманова А.И., Гатаулин Р.Г. и др. Роль ожирения в развитии фибрилляции предсердий: современное состояние проблемы // Кардиоваскулярная терапия и профилактика. 2019. Т. 18, № 4. С. 109–114. DOI: 10.15829/1728880020194109114

[9] Camm AJ, Lip GY, De Caterina R, et al. 2012 focused update of the ESC guidelines for the management of atrial fibrillation: an update of the 2010 ESC guidelines for the management of atrial fibrillation — developed with the special contribution of the European Heart Rhythm Association. Eur Heart J. 2012;33(21):2719–2747. DOI: 10.1093/eurheartj/ehs253

[10] Camm A.J, Lip G.Y., De Caterina R. et al. 2012 focused update of the ESC guidelines for the management of atrial fibrillation: an update of the 2010 ESC guidelines for the management of atrial fibrillation — developed with the special contribution of the European Heart Rhythm Association // Eur. Heart J. 2012. Vol. 33, No. 21. P. 2719–2747. DOI: 10.1093/eurheartj/ehs253

[11] Zhernakova Yu. Hyperuricemia as a risk factor for cardiovascular disease - what’s new? Medical Alphabet. 2020;(13):5–11. (In Russ.). DOI: 10.33667/2078-5631-2020-13-5-11

[12] Жернакова Ю.В. Гиперурикемия как фактор риска сердечно-сосудистых заболеваний — что нового? // Медицинский алфавит. 2020. № 13. С. 5–11. DOI: 10.33667/2078-5631-2020-13-5-11

[13] Bilchenko A. Hyperuricemia as a risk factor of cardiovascular morbidity and mortality.Korrekciya giperurikemii kak faktora riska serdechno-sosudistoj zabolevaemosti i smertnosti // Novosti mediciny i farmacii. 2011;5(389):53–58. (In Russ.).

[14] Бильченко А.В. Коррекция гиперурикемии как фактора риска сердечно-сосудистой заболеваемости и смертности // Новости медицины и фармации. 2011. № 5(389). С. 53–58.

[15] Donskov A, Balkarov I, Dadina Z, et al. Urate kidney damage and metabolic changes in patients with arterial hypertension. Terapevticheskij Arkhiv. 1999;(6):53–56. (In Russ.).

[16] Донсков А.С., Балкаров И.М., Дадина З.М. и др. Уратное поражение почек и метаболические сдвиги у пациентов с артериальной гипертензией // Терапевтический Архив. 1999. № 6. С. 53–56.

[17] Becker JF, Schumacher HR Jr, Wortmann RL. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med. 2005;353:2450–2461. DOI: 10.1056/NEJMoa050373

[18] Becker J.F., Schumacher H.R.Jr., Wortmann R.L. Febuxostat compared with allopurinol in patients with hyperuricemia and gout // N. Engl. J. Med. 2005. Vol. 353, No. 23. P. 2450–2461. DOI: 10.1056/NEJMoa050373

[19] France LV, Pahor M, Di Bari M, et al. Serum uric acid, diuretic treatment and risk of cardiovascular events in the Systolic Hypertension in the elderly Program (SHEP). J Hypertens. 2000;18(8):1149–1154. DOI: 10.1097/00004872-200018080-00021

[20] France L.V., Pahor M., Di Bari M. et al. Serum uric acid, diuretic treatment and risk of cardiovascular events in the Systolic Hypertension in the elderly Program (SHEP) // J. Hypertens. 2000. Vol. 18, No. 8. P. 1149–1154. DOI: 10.1097/00004872-200018080-00021

[21] Zhu Y, Pandya BJ, Choi HK. Prevalence of gout and hyperuricemia in the US general population. The National Health and Nutrition Examination Survey 2007–2008. Arthritis Rheum. 2011;63(10): 3136–3141. DOI: 10.1002/art.30520

[22] Zhu Y., Pandya B.J., Choi H.K. Prevalence of gout and hyperuricemia in the US general population. The National Health and Nutrition Examination Survey 2007–2008 // Arthritis. Rheum. 2011. Vol. 63, No. 10. P. 3136–3141. DOI: 10.1002/art.30520

[23] Liu B, Wang T, Zhao HN, et al. The prevalence of hyperuricemia in China: a meta-analysis. BMC Public Health. 2011;11:832. DOI: 10.1186/1471-2458-11-832

[24] Liu B., Wang T., Zhao H.N. et al. The prevalence of hyperuricemia in China: a meta-analysis // BMC Public Health. 2011. Vol. 11. P. 832. DOI: 10.1186/1471-2458-11-832

[25] Qiu L, Cheng X, Wu J, et al. Prevalence of hyperuricemia and its related risk factors in healthy adults from Northern and Northeastern Chinese provinces. BMC Public health. 2013;13:664. DOI: 10.1186/1471-2458-13-664

[26] Qiu L., Cheng X.Q., Wu J. et al. Prevalence of hyperuricemia and its related risk factors in healthy adults from Northern and Northeastern Chinese provinces // BMC Public health. 2013. Vol. 13. P. 664. DOI: 10.1186/1471-2458-13-664

[27] Shal’nova SA, Deev AD, Artamonova GV, et al. Hyperuricemia and its correlates in the Russian population (results of the ESSE-RF epidemiological study). Rational Pharmacotherapy in Cardiology. 2014;10(2):153–159. (In Russ.).

[28] Шальнова С.А., Деев А.Д., Артамонова Г.В. и др. Гиперурикемия и ее корреляты в российской популяции (результаты эпидемиологического исследования ЭССЕ-РФ) // Рациональная Фармакотерапия в Кардиологии. 2014. Т. 10, No. 2. С. 153–159.

[29] Wu AH, Gladden JD, Ahmed M, et al. Relation of serum uric acid to cardiovascular disease. Int J Cardiol. 2016;213:4–7. DOI: 10.1016/j.ijcard.2015.08.110

[30] Wu A.H., Gladden J.D., Ahmed M. et al. Relation of serum uric acid to cardiovascular disease // Int. J. Cardiol. 2016. Vol. 213. P. 4–7. DOI: 10.1016/j.ijcard.2015.08.110

[31] Hou L, Zhang M, Han W, et al. Influence of salt intake on association of blood uric acid with hypertension and related cardiovascular risk. PLoS One. 2016;11(4):e0150451. DOI: 10.1371/journal.pone.0150451

[32] Hou L., Zhang M., Han W. et al. Influence of salt intake on association of blood uric acid with hypertension and related cardiovascular risk // PLoS One. 2016. Vol. 11, No. 4. P. e0150451. DOI: 10.1371/journal.pone.0150451

[33] Ando K, Takahashi H, Watanabe T, et al. Impact of serum uric acid levels on coronary plaque stability evaluated using integrated backscatter intravascular ultrasound in patients with coronary artery disease. J Atheroscler Thromb. 2016;23(8):932–939. DOI: 10.5551/jat.33951

[34] Ando K., Takahashi H., Watanabe T. et al. Impact of serum uric acid levels on coronary plaque stability evaluated using integrated backscatter intravascular ultrasound in patients with coronary artery disease // J. Atheroscler. Thromb. 2016. Vol. 23, No. 8. P. 932–939. DOI: 10.5551/jat.33951

[35] Bespalova I, Kalyuzhin V, Medyantsev Yu. Asyptomatic hyperuricemia as a metabolic syndrome component. Bulletin of Siberian Medicine. 2012;11(3):14–17. (In Russ.). DOI: 10.20538/1682-0363-2012-3-14-17

[36] Беспалова И.Д., Калюжин В.В., Медянцев Ю.А. Бессимптомная гиперурикемия как компонент метаболического синдрома // Бюллетень сибирской медицины. 2012. Т. 11, № 3. С. 14–17. DOI: 10.20538/1682-0363-2012-3-14-17

[37] MacGowan S, Regan M, Malone C, et al. Superoxide radical and xanthine oxidoreductase activity in the human heart during cardiac operations. Ann Thorac Surg. 1995;60(5):1289–1293. DOI: 10.1016/0003-4975(95)00616-S

[38] MacGowan S., Regan M., Malone C. et al. Superoxide radical and xanthine oxidoreductase activity in the human heart during cardiac operations // Ann. Thorac. Surg. 1995. Vol. 60, No. 5. P. 1289–1293. DOI: 10.1016/0003-4975(95)00616-S

[39] Korantzopoulos P, Letsas K, Liu T. Xanthine oxidase and uric acid in atrial fibrillation. Front Physiol. 2012;3:150. DOI: 10.3389/fphys.2012.00150

[40] Korantzopoulos P., Letsas K., Liu T. Xanthine oxidase and uric acid in atrial fibrillation // Front. Physiol. 2012. Vol. 3. P. 150. DOI: 10.3389/fphys.2012.00150

[41] Letsas K, Korantzopoulos P, Filippatos G, et al. Uric acid elevation in atrial fibrillation. Hellenic J Cardiol. 2010;51(3):209–213.

[42] Letsas K., Korantzopoulos P., Filippatos G. et al. Uric acid elevation in atrial fibrillation // Hellenic J. Cardiol. 2010. Vol. 51, No.3. P. 209–213.

[43] Yatskevich ES, Snezhitskiy VA. The influence of aldosterone and its antagonists on myocardial remodeling in ratients with atrial fibrillation. Journal of Grodno State Medical University. 2012;(4(40)):5–9. (In Russ.).

[44] Яцкевич Е.С., Снежицкий В.А. Влияние альдостерона и его антагонистов на ремоделирование миокарда у пациентов с фибрилляцией предсердий // Журнал Гродненского государственного медицинского университета. 2012. № 4(40). С. 5–9.

[45] Delcayre C, Swynghedauw B. Molecular mechanisms of myocardial remodelling. The role of aldosterone. J Mol Cell Cardiol. 2002;34(12):1577–1584. DOI: 10.1006/jmcc.2002.2088

[46] Delcayre C., Swynghedauw B. Molecular mechanisms of myocardial remodelling. The role of aldosterone // J. Mol. Cell. Cardiol. 2002. Vol. 34, No. 12. P. 1577–1584. DOI: 10.1006/jmcc.2002.2088

[47] Schotten U, Verheule S, Kirchhof P, Goette A. Pathophysiological mechanisms of atrial fibrillation: A translational appraisal. Physiol Rev. 2011;91(1):265–325. DOI: 10.1152/physrev.00031.2009

[48] Schotten U., Verheule S., Kirchhof P., Goette A. Pathophysiological mechanisms of atrial fibrillation: A translational appraisal // Physiol. Rev. 2011. Vol. 91, No. 1. P. 265–325. DOI: 10.1152/physrev.00031.2009

[49] Patterson E, Jackman WM, Beckman KJ, et al. Spontaneous pulmonary vein firing in man: Relationship to tachycardia-pause early afterdepolarizations and triggered arrhythmia in canine pulmonary veins in vitro. J Cardiovasc Electrophysiol. 2007;18(10):1067–1075. DOI: 10.1111/j.1540-8167.2007.00909.x

[50] Patterson E., Jackman W.M., Beckman K.J. et al. Spontaneous pulmonary vein firing in man: Relationship to tachycardia-pause early afterdepolarizations and triggered arrhythmia in canine pulmonary veins in vitro // J. Cardiovasc. Electrophysiol. 2007. Vol. 18, No. 10. P. 1067–1075. DOI: 10.1111/j.1540-8167.2007.00909.x

[51] Zholbaeva A, Tabina A, Goluhova E. Molecular mechanisms of atrial fibrillation: “ideal” marker searching. Creative Cardiology. 2015;(2):40–53. (In Russ.). DOI: 10.15275/kreatkard.2015.02.04

[52] Жолбаева А.З., Табина А.Е., Голухова Е.З. Молекулярные механизмы фибрилляции предсердий: в поиске «идеального» маркера // Креативная кардиология. 2015. № 2. С. 40–53. DOI: 10.15275/kreatkard.2015.02.04

[53] Dobrev D, Friedrich A, Voigt N, et al. The G protein-gated potassium current I(K,ACh) is constitutively active in patients with chronic atrial fibrillation. Circulation. 2005;112(24):3697–3706. DOI: 10.1161/CIRCULATIONAHA.105.575332

[54] Dobrev D., Friedrich A., Voigt N. et al. The G protein-gated potassium current I(K,ACh) is constitutively active in patients with chronic atrial fibrillation // Circulation. 2005. Vol. 112, No. 24. P. 3697–3706. DOI: 10.1161/CIRCULATIONAHA.105.575332

[55] Snezhitskiy V. Electrophysiological atrial and sinus nodal remodeling phenomenon: mechanisms of development and pathogenesis. Clinical Medicine (Russian Journal). 2004;82(11): 10–14. (In Russ.).

[56] Снежицкий В.А. Феномен электрофизиологического ремоделирования предсердий и синусового узла: механизмы развития и патогенез // Клиническая медицина. 2004. Т. 82, № 11. С. 10–14.

[57] Jia G, Habibi J, Bostick BP, et al. Uric acid promotes left ventricular diastolic dysfunction in mice fed a Western diet. Hypertension. 2015;65(3):531–539. DOI: 10.1161/HYPERTENSIONAHA.114.04737

[58] Jia G., Habibi J., Bostick B.P. et al. Uric acid promotes left ventricular diastolic dysfunction in mice fed a Western diet // Hypertension. 2015. Vol. 65, No. 3. P. 531–539. DOI: 10.1161/HYPERTENSIONAHA.114.04737

[59] Maharani N, Ting YK, Cheng J, et al. Molecular mechanisms underlying urate-induced enhancement of Kv1.5 channel expression in HL-1 atrial myocytes. Circ J. 2015;79(12):2659–2668. DOI: 10.1253/circj.CJ-15-0416

[60] Maharani N., Ting Y.K., Cheng J. et al. Molecular mechanisms underlying urate-induced enhancement of Kv1.5 channel expression in HL-1 atrial myocytes // Circ. J. 2015. Vol. 79, No. 12. P. 2659–2668. DOI: 10.1253/circj.CJ-15-0416

[61] Niforou K, Cheimonidou C, Trougakos IP. Molecular chaperones and proteostasis regulation during redox imbalance. Redox Biol. 2014;2:323–332. DOI: 10.1016/j.redox.2014.01.017

[62] Niforou K., Cheimonidou C., Trougakos I.P. Molecular chaperones and proteostasis regulation during redox imbalance // Redox. Biol. 2014. Vol. 2. P. 323–332. DOI: 10.1016/j.redox.2014.01.017

[63] Giannopoulos G, Cleman MW, Deftereos S. Inflammation fueling atrial fibrillation substrate: Seeking ways to “cool” the heart. Med Chem. 2014;10(7):663–671. DOI: 10.2174/1573406410666140318110100

[64] Giannopoulos G., Cleman M.W., Deftereos S. Inflammation fueling atrial fibrillation substrate: Seeking ways to “cool” the heart // Med. Chem. 2014. Vol. 10, No. 7. P. 663–671. DOI: 10.2174/1573406410666140318110100

[65] Bubeshka DA, Snezhitskiy VA, Shulika VR. Biomarkers of inflammation in patients with nonvalvular atrial fibrillation and left ventricular systolic dysfunction. Medical News. 2017;(4):69–72. (In Russ.)

[66] Бубешка Д.А., Снежицкий В.А., Шулика В.Р. Биомаркеры воспаления у пациентов с неклапанной фибрилляцией предсердий и систолической дисфункцией левого желудочка // Медицинские новости. 2017. № 4. С. 69–72.

[67] Levy M, Thaiss CA, Elinav E. Taming the inflammasome. Nat Med. 2015;21(3):213–215. DOI: 10.1038/nm.3808

[68] Levy M., Thaiss C.A., Elinav E. Taming the inflammasome // Nat. Med. 2015. Vol. 21, No. 3. P. 213–215. DOI: 10.1038/nm.3808

[69] Bruins P, te Velthuis H, Yazdanbakhsh AP, et al. Activation of the complement system during and after cardiopulmonary bypass surgery: Postsurgery activation involves C-reactive protein and is associated with postoperative arrhythmia. Circulation. 1997;96(10):3542–3548. DOI: 10.1161/01.cir.96.10.3542

[70] Bruins P., te Velthuis H., Yazdanbakhsh A.P. et al. Activation of the complement system during and after cardiopulmonary bypass surgery: Postsurgery activation involves C-reactive protein and is associated with postoperative arrhythmia // Circulation. 1997. Vol. 96, No. 10. P. 3542–3548. DOI: 10.1161/01.cir.96.10.3542

[71] Yao C, Veleva T, Scott LJ, et al. Enhanced cardiomyocyte NLRP3 inflammasome signaling promotes atrial fibrillation. Circulation. 2018;138(20):2227–2242. DOI: 10.1161/CIRCULATIONAHA.118.035202

[72] Yao C., Veleva T., Scott L.D. Jr. et al. Enhanced cardiomyocyte NLRP3 inflammasome signaling promotes atrial fibrillation // Circulation. 2018. Vol. 138, No. 20. P. 2227–2242. DOI: 10.1161/CIRCULATIONAHA.118.035202

[73] Putko BN, Wang Z, Lo J, et al. Circulating levels of tumor necrosis factor-alpha receptor 2 are increased in heart failure with preserved ejection fraction relative to heart failure with reduced ejection fraction: Evidence for a divergence in pathophysiology. PLoS One. 2014;9(6):e99495. DOI: 10.1371/journal.pone.0099495

[74] Putko B.N., Wang Z., Lo J. et al. Circulating levels of tumor necrosis factor-alpha receptor 2 are increased in heart failure with preserved ejection fraction relative to heart failure with reduced ejection fraction: Evidence for a divergence in pathophysiology // PLoS One. 2014. Vol. 9, No. 6. P. e99495. DOI: 10.1371/journal.pone.0099495

[75] Liew R, Khairunnisa K, Gu Y, et al. Role of tumor necrosis factor-α in the pathogenesis of atrial fibrosis and development of an arrhythmogenic substrate. Circ J. 2013;77(5):1171–1179. DOI: 10.1253/circj.cj-12-1155

[76] Liew R., Khairunnisa K., Gu Y. et al. Role of tumor necrosis factor-α in the pathogenesis of atrial fibrosis and development of an arrhythmogenic substrate // Circ. J. 2013. Vol. 77, No. 5. P. 1171–1179. DOI: 10.1253/circj.cj-12-1155

[77] Hu YF, Chen YJ, Lin YJ, Chen SA. Inflammation and the pathogenesis of atrial fibrillation. Nat Rev Cardiol. 2015;12(4):230–243. DOI: 10.1038/nrcardio.2015.2

[78] Hu Y.F., Chen Y.J., Lin Y.J., Chen S.A. Inflammation and the pathogenesis of atrial fibrillation // Nat. Rev. Cardiol. 2015. Vol. 12, No. 4. P. 230–243. DOI: 10.1038/nrcardio.2015.2

[79] Chung MK, Martin DO, Sprecher D, et al. C-reactive protein elevation in patients with atrial arrhythmias: Inflammatory mechanisms and persistence of atrial fibrillation. Circulation. 2001;104(24):2886–2891. DOI: 10.1161/hc4901.101760

[80] Chung M.K., Martin D.O., Sprecher D. et al. C-reactive protein elevation in patients with atrial arrhythmias: Inflammatory mechanisms and persistence of atrial fibrillation // Circulation. 2001. Vol. 104, No. 24. P. 2886–2891. DOI: 10.1161/hc4901.101760

[81] Chen Y, Xia Y, Han X, et al. Association between serum uric acid and atrial fibrillation: A cross-sectional community-based study in China. BMJ Open. 2017;7(12):e019037. DOI: 10.1136/ bmjopen-2017-019037

[82] Chen Y., Xia Y., Han X. et al. Association between serum uric acid and atrial fibrillation: A cross-sectional community-based study in China // BMJ Open. 2017. Vol. 7, No. 12. P. e019037. DOI: 10.1136/ bmjopen-2017-019037

[83] Kuwabara M, Niwa K, Nishihara S, et al. Hyperuricemia is an independent competing risk factor for atrial fibrillation. Int J Cardiol. 2017;231:137–142. DOI: 10.1016/j.ijcard.2016.11.268

[84] Kuwabara M., Niwa K., Nishihara S. et al. Hyperuricemia is an independent competing risk factor for atrial fibrillation // Int. J. Cardiol. 2017. Vol. 231. P. 137–142. DOI: 10.1016/j.ijcard.2016.11.268

[85] Zhang CH, Huang DS, Shen D. Association between serum uric acid levels and atrial fibrillation risk. Cell Physiol Biochem. 2016;38(4):1589–1595. DOI: 10.1159/000443099

[86] Zhang C.H., Huang D.S., Shen D. et al. Association between serum uric acid levels and atrial fibrillation risk // Cell. Physiol. Biochem. 2016. N. 38, No. 4. P. 1589–1595. DOI: 10.1159/000443099

[87] Deshko M, Snezhitskiy V, Madekina G, et al. Prognostic value of hyperuricemia in patients with atrial fibrillation and heart failure with preserved ejection fraction. Cardiology. 2015;55(10):52–57. (In Russ.). DOI: 10.18565/cardio.2015.10.52-57

[88] Дешко М.С., Снежицкий В.А., Мадекина Г.А. и др. Прогностическое значение гиперурикемии у пациентов с фибрилляцией предсердий и сердечной недостаточностью с сохранной фракцией выброса // Кардиология. 2015. Т. 55, № 10. С. 52–57. DOI: 10.18565/cardio.2015.10.52-57

[89] Kepurko TL, Snezhitskiy VA. Hyperuricemia as a risk factor for atrial fibrillation progression. Cardiology in Belarus. 2018;10(1): 125–132.

[90] Кепурко Т.Л., Снежицкий В.А. Гиперурикемия как фактор риска развития фибрилляции предсердий // Кардиология в Беларуси. 2018. Т. 10, № 1. С. 125–132.

[91] Nyrnes A, Toft I, Njølstad I. Uric acid is associated with future atrial fibrillation: an 11-year follow-up of 6308 men and women-the Tromso Study. Europace. 2014;16(3):320–326. DOI: 10.1093/europace/eut260

[92] Nyrnes A., Toft I., Njølstad I. et al. Uric acid is associated with future atrial fibrillation: an 11-year follow-up of 6308 men and women-the Tromso Study // Europace. 2014. Vol. 16, No. 3. P. 320–326. DOI: 10.1093/europace/eut260

RIGHTS & PERMISSIONS

Barysenka T.L., Snezhitskiy V.A.